JPRN-jRCT2080222524已完成1 期
An open-label, dose escalation, phase I study to evaluate the tolerability, safety and pharmacokinetics of afuresertib monotherapy and in combination with bortezomib and dexamethasone in Japanese relapsed multiple myeloma patients.
适应症
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- ovartis
- 入组人数
- 18
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- ot applicable 至 ot applicable（—）
- 性别
- All
入选标准
- •Japanese Relapsed Multiple Myeloma Patients
排除标准
- •Chemotherapy, radiotherapy, immunotherapy or other anti-myeloma therapy within 28 days prior to enrolment. In addition, any toxicity (except alopecia) should be recovered to <=Grade 1 by National Cancer Institute - Common Terminology Criteria for Adverse Events (NCI-CTCAE), version 4.0.
研究者
相似试验
招募中
1 期
A Study of TAK-676 as Single Agent and TAK-676 in Combination With Pembrolizumab in Adults With Advanced or Metastatic Solid TumorsSolid NeoplasmCTIS2023-505627-30-00Takeda Development Center Americas Inc.368
招募中
不适用
A dose-escalation, open label phase I study to assess the safety, feasibility and preliminary efficacy of HA-1H TCR modified T cells, MDG1021, in patients with relapsed or persistent hematologic malignancies after allogeneic hematological stem cell transplantation with or without unmanipulated donor lymphocyte infusion.blood diseaseNL-OMON55022Miltenyi Biomedicine29
尚未招募
1 期
A Phase I, Open label, Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Anti tumor Effects of Recombinant Oncolytic Virus M1 (M1 c6v1) for Treatment of Patients with Locally Advanced or Metastatic Solid TumorsSolid TumorsJPRN-jRCT2063230079Sawai Yoshihito12
已完成
不适用
A phase I, open-label, dose escalation study to investigate the safety, pharmacokinetics, pharmacodynamics and clinical activity of GSK3326595 in subjects with solid tumors and non-Hodgkin*s lymphoma.solid tumors, non-hodgkin's lymphomasolid tumors and non-Hodgkins lymphomaNL-OMON53127GlaxoSmithKline39
已完成
1 期
A phase-I, open label, dose-escalation, safety, tolerability andpharmacokinetics study of Nor-ursodeoxycholic acid tablets 500 mgCTRI/2022/11/047561Shilpa Medicare Limited42